Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

J&J sets new pharma standard for sharing clinical trial data

Chooses Yale to act as independent trial data request review body

- PMLiVE

Janssen announces new group to tackle global health

Will implement R&D and access strategies to support areas with unmet public health need

J&J expected to make best use of digital in 2014

Company's strong approach to marketing strategy praised in Digital Futures 2014 survey

- PMLiVE

J&J earnings leap on buoyant pharma sales

CEO Alex Gorsky praises "outstanding" pharmaceutical performance

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

- PMLiVE

J&J’s Imbruvica tops Arzerra in phase III trial

Shows improvement over GSK’s drug in haematological malignancies

- PMLiVE

Celgene wins EU pancreatic cancer approval for Abraxane

Adds to drug's existing breast cancer indication

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links